http://streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Mon, 15 Jun 2026 16:07:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Inhibrx+Biosciences%2C++++++For%3A+Jun+15/26647343.html si-local-file:///var/storage/secattach/20260615/26647343.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Inhibrx+Biosciences%2C++++++For%3A+Jun+15/26647343.html Mon, 15 Jun 2026 16:07:00 -0400 INBX O.21755854 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Inhibrx+Biosciences%2C++++++For%3A+Jun+15/26647343.html si-local-file:///var/storage/secattach/20260615/26647343.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Inhibrx+Biosciences%2C++++++For%3A+Jun+15/26647343.html Mon, 15 Jun 2026 16:07:00 -0400 INBX O.21755854 http://www.streetinsider.com/Corporate+News/Inhibrx+receives+FDA+acceptance+for+ozekibart+drug+application/26645174.html <p>Inhibrx Biosciences Inc. (NASDAQ: INBX) announced that the U.S. Food and Drug Administration has accepted its Biologics License Application for ozekibart, a treatment for patients with unresectable or metastatic conventional chondrosarcoma.</p><p>The FDA set a Prescription Drug User Fee Act goal date of April 14, 2027, and identified no filing review issues. If approved, ozekibart would become the first FDA-approved treatment for this form of bone cancer.</p><p>The application is supported by results from the ChonDRAgon study, a randomized, placebo-controlled trial involving 206 patients across 67 sites worldwide. The study met its primary endpoint, showing ozekibart achieved a 52% reduction in risk http://www.streetinsider.com/Corporate+News/Inhibrx+receives+FDA+acceptance+for+ozekibart+drug+application/26645174.html Mon, 15 Jun 2026 09:15:35 -0400 INBX http://www.streetinsider.com/FDA/Inhibrx+receives+FDA+acceptance+for+ozekibart+drug+application/26645174.html <p>Inhibrx Biosciences Inc. (NASDAQ: INBX) announced that the U.S. Food and Drug Administration has accepted its Biologics License Application for ozekibart, a treatment for patients with unresectable or metastatic conventional chondrosarcoma.</p><p>The FDA set a Prescription Drug User Fee Act goal date of April 14, 2027, and identified no filing review issues. If approved, ozekibart would become the first FDA-approved treatment for this form of bone cancer.</p><p>The application is supported by results from the ChonDRAgon study, a randomized, placebo-controlled trial involving 206 patients across 67 sites worldwide. The study met its primary endpoint, showing ozekibart achieved a 52% reduction in risk http://www.streetinsider.com/FDA/Inhibrx+receives+FDA+acceptance+for+ozekibart+drug+application/26645174.html Mon, 15 Jun 2026 09:15:35 -0400 INBX http://www.streetinsider.com/Press+Releases/Inhibrx+Announces+U.S.+FDA+Acceptance+of+BLA+for+Ozekibart+in+Patients+with+Conventional+Chondrosarcoma/26645164.html <div class="xn-content"> <ul type="disc"><li><b><i>No filing review issues identified by FDA with PDUFA goal date set for <chron>April 14, 2027</chron></i></b></li><li><b><i>If Approved, Ozekibart Would Be the First and Only FDA-Approved Treatment for Unresectable or Metastatic Conventional Chondrosarcoma </i></b></li></ul><p><span class="legendSpanClass"><location value="LU/us.ca.sandgo" idsrc="xmltag.org" >SAN DIEGO</location></span>, <span class="legendSpanClass"><chron>June 15, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:INBX" idsrc="xmltag.org" >Inhibrx Biosciences, Inc.</span> (Nasdaq: INBX) ("<span value="NASDAQ-NMS:INBX" idsrc="xmltag.org" >Inhibrx</span>" or the "Company"), a clinical-stage biopharmaceutical company focused on developing novel biologic therapeutic candidates, today announced that the <span value="ACORN:0682203466" idsrc="xmltag.org" >U.S. Food and Drug Administration</span> (FDA) has accepted for filing its Biologics License Application (BLA) seeking approval of ozekibart (INBRX-109) for http://www.streetinsider.com/Press+Releases/Inhibrx+Announces+U.S.+FDA+Acceptance+of+BLA+for+Ozekibart+in+Patients+with+Conventional+Chondrosarcoma/26645164.html Mon, 15 Jun 2026 09:15:00 -0400 A.06822034 INBX O.20026344 O.21755854 http://www.streetinsider.com/Press+Releases/Inhibrx+Announces+U.S.+FDA+Acceptance+of+BLA+for+Ozekibart+in+Patients+with+Conventional+Chondrosarcoma/26645164.html <div class="xn-content"> <ul type="disc"><li><b><i>No filing review issues identified by FDA with PDUFA goal date set for <chron>April 14, 2027</chron></i></b></li><li><b><i>If Approved, Ozekibart Would Be the First and Only FDA-Approved Treatment for Unresectable or Metastatic Conventional Chondrosarcoma </i></b></li></ul><p><span class="legendSpanClass"><location value="LU/us.ca.sandgo" idsrc="xmltag.org" >SAN DIEGO</location></span>, <span class="legendSpanClass"><chron>June 15, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:INBX" idsrc="xmltag.org" >Inhibrx Biosciences, Inc.</span> (Nasdaq: INBX) ("<span value="NASDAQ-NMS:INBX" idsrc="xmltag.org" >Inhibrx</span>" or the "Company"), a clinical-stage biopharmaceutical company focused on developing novel biologic therapeutic candidates, today announced that the <span value="ACORN:0682203466" idsrc="xmltag.org" >U.S. Food and Drug Administration</span> (FDA) has accepted for filing its Biologics License Application (BLA) seeking approval of ozekibart (INBRX-109) for http://www.streetinsider.com/Press+Releases/Inhibrx+Announces+U.S.+FDA+Acceptance+of+BLA+for+Ozekibart+in+Patients+with+Conventional+Chondrosarcoma/26645164.html Mon, 15 Jun 2026 09:15:00 -0400 A.06822034 INBX O.20026344 O.21755854 http://www.streetinsider.com/Press+Releases/Inhibrx+Announces+U.S.+FDA+Acceptance+of+BLA+for+Ozekibart+in+Patients+with+Conventional+Chondrosarcoma/26645164.html <div class="xn-content"> <ul type="disc"><li><b><i>No filing review issues identified by FDA with PDUFA goal date set for <chron>April 14, 2027</chron></i></b></li><li><b><i>If Approved, Ozekibart Would Be the First and Only FDA-Approved Treatment for Unresectable or Metastatic Conventional Chondrosarcoma </i></b></li></ul><p><span class="legendSpanClass"><location value="LU/us.ca.sandgo" idsrc="xmltag.org" >SAN DIEGO</location></span>, <span class="legendSpanClass"><chron>June 15, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:INBX" idsrc="xmltag.org" >Inhibrx Biosciences, Inc.</span> (Nasdaq: INBX) ("<span value="NASDAQ-NMS:INBX" idsrc="xmltag.org" >Inhibrx</span>" or the "Company"), a clinical-stage biopharmaceutical company focused on developing novel biologic therapeutic candidates, today announced that the <span value="ACORN:0682203466" idsrc="xmltag.org" >U.S. Food and Drug Administration</span> (FDA) has accepted for filing its Biologics License Application (BLA) seeking approval of ozekibart (INBRX-109) for http://www.streetinsider.com/Press+Releases/Inhibrx+Announces+U.S.+FDA+Acceptance+of+BLA+for+Ozekibart+in+Patients+with+Conventional+Chondrosarcoma/26645164.html Mon, 15 Jun 2026 09:15:00 -0400 A.06822034 INBX O.20026344 O.21755854 http://www.streetinsider.com/Press+Releases/Inhibrx+Announces+U.S.+FDA+Acceptance+of+BLA+for+Ozekibart+in+Patients+with+Conventional+Chondrosarcoma/26645164.html <div class="xn-content"> <ul type="disc"><li><b><i>No filing review issues identified by FDA with PDUFA goal date set for <chron>April 14, 2027</chron></i></b></li><li><b><i>If Approved, Ozekibart Would Be the First and Only FDA-Approved Treatment for Unresectable or Metastatic Conventional Chondrosarcoma </i></b></li></ul><p><span class="legendSpanClass"><location value="LU/us.ca.sandgo" idsrc="xmltag.org" >SAN DIEGO</location></span>, <span class="legendSpanClass"><chron>June 15, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:INBX" idsrc="xmltag.org" >Inhibrx Biosciences, Inc.</span> (Nasdaq: INBX) ("<span value="NASDAQ-NMS:INBX" idsrc="xmltag.org" >Inhibrx</span>" or the "Company"), a clinical-stage biopharmaceutical company focused on developing novel biologic therapeutic candidates, today announced that the <span value="ACORN:0682203466" idsrc="xmltag.org" >U.S. Food and Drug Administration</span> (FDA) has accepted for filing its Biologics License Application (BLA) seeking approval of ozekibart (INBRX-109) for http://www.streetinsider.com/Press+Releases/Inhibrx+Announces+U.S.+FDA+Acceptance+of+BLA+for+Ozekibart+in+Patients+with+Conventional+Chondrosarcoma/26645164.html Mon, 15 Jun 2026 09:15:00 -0400 A.06822034 INBX O.20026344 O.21755854 http://www.streetinsider.com/PRNewswire/Inhibrx+Announces+U.S.+FDA+Acceptance+of+BLA+for+Ozekibart+in+Patients+with+Conventional+Chondrosarcoma/26645164.html <div class="xn-content"> <ul type="disc"><li><b><i>No filing review issues identified by FDA with PDUFA goal date set for <chron>April 14, 2027</chron></i></b></li><li><b><i>If Approved, Ozekibart Would Be the First and Only FDA-Approved Treatment for Unresectable or Metastatic Conventional Chondrosarcoma </i></b></li></ul><p><span class="legendSpanClass"><location value="LU/us.ca.sandgo" idsrc="xmltag.org" >SAN DIEGO</location></span>, <span class="legendSpanClass"><chron>June 15, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:INBX" idsrc="xmltag.org" >Inhibrx Biosciences, Inc.</span> (Nasdaq: INBX) ("<span value="NASDAQ-NMS:INBX" idsrc="xmltag.org" >Inhibrx</span>" or the "Company"), a clinical-stage biopharmaceutical company focused on developing novel biologic therapeutic candidates, today announced that the <span value="ACORN:0682203466" idsrc="xmltag.org" >U.S. Food and Drug Administration</span> (FDA) has accepted for filing its Biologics License Application (BLA) seeking approval of ozekibart (INBRX-109) for http://www.streetinsider.com/PRNewswire/Inhibrx+Announces+U.S.+FDA+Acceptance+of+BLA+for+Ozekibart+in+Patients+with+Conventional+Chondrosarcoma/26645164.html Mon, 15 Jun 2026 09:15:00 -0400 A.06822034 INBX O.20026344 O.21755854 http://www.streetinsider.com/PRNewswire/Inhibrx+Announces+U.S.+FDA+Acceptance+of+BLA+for+Ozekibart+in+Patients+with+Conventional+Chondrosarcoma/26645164.html <div class="xn-content"> <ul type="disc"><li><b><i>No filing review issues identified by FDA with PDUFA goal date set for <chron>April 14, 2027</chron></i></b></li><li><b><i>If Approved, Ozekibart Would Be the First and Only FDA-Approved Treatment for Unresectable or Metastatic Conventional Chondrosarcoma </i></b></li></ul><p><span class="legendSpanClass"><location value="LU/us.ca.sandgo" idsrc="xmltag.org" >SAN DIEGO</location></span>, <span class="legendSpanClass"><chron>June 15, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:INBX" idsrc="xmltag.org" >Inhibrx Biosciences, Inc.</span> (Nasdaq: INBX) ("<span value="NASDAQ-NMS:INBX" idsrc="xmltag.org" >Inhibrx</span>" or the "Company"), a clinical-stage biopharmaceutical company focused on developing novel biologic therapeutic candidates, today announced that the <span value="ACORN:0682203466" idsrc="xmltag.org" >U.S. Food and Drug Administration</span> (FDA) has accepted for filing its Biologics License Application (BLA) seeking approval of ozekibart (INBRX-109) for http://www.streetinsider.com/PRNewswire/Inhibrx+Announces+U.S.+FDA+Acceptance+of+BLA+for+Ozekibart+in+Patients+with+Conventional+Chondrosarcoma/26645164.html Mon, 15 Jun 2026 09:15:00 -0400 A.06822034 INBX O.20026344 O.21755854 http://www.streetinsider.com/PRNewswire/Inhibrx+Announces+U.S.+FDA+Acceptance+of+BLA+for+Ozekibart+in+Patients+with+Conventional+Chondrosarcoma/26645164.html <div class="xn-content"> <ul type="disc"><li><b><i>No filing review issues identified by FDA with PDUFA goal date set for <chron>April 14, 2027</chron></i></b></li><li><b><i>If Approved, Ozekibart Would Be the First and Only FDA-Approved Treatment for Unresectable or Metastatic Conventional Chondrosarcoma </i></b></li></ul><p><span class="legendSpanClass"><location value="LU/us.ca.sandgo" idsrc="xmltag.org" >SAN DIEGO</location></span>, <span class="legendSpanClass"><chron>June 15, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:INBX" idsrc="xmltag.org" >Inhibrx Biosciences, Inc.</span> (Nasdaq: INBX) ("<span value="NASDAQ-NMS:INBX" idsrc="xmltag.org" >Inhibrx</span>" or the "Company"), a clinical-stage biopharmaceutical company focused on developing novel biologic therapeutic candidates, today announced that the <span value="ACORN:0682203466" idsrc="xmltag.org" >U.S. Food and Drug Administration</span> (FDA) has accepted for filing its Biologics License Application (BLA) seeking approval of ozekibart (INBRX-109) for http://www.streetinsider.com/PRNewswire/Inhibrx+Announces+U.S.+FDA+Acceptance+of+BLA+for+Ozekibart+in+Patients+with+Conventional+Chondrosarcoma/26645164.html Mon, 15 Jun 2026 09:15:00 -0400 A.06822034 INBX O.20026344 O.21755854 http://www.streetinsider.com/PRNewswire/Inhibrx+Announces+U.S.+FDA+Acceptance+of+BLA+for+Ozekibart+in+Patients+with+Conventional+Chondrosarcoma/26645164.html <div class="xn-content"> <ul type="disc"><li><b><i>No filing review issues identified by FDA with PDUFA goal date set for <chron>April 14, 2027</chron></i></b></li><li><b><i>If Approved, Ozekibart Would Be the First and Only FDA-Approved Treatment for Unresectable or Metastatic Conventional Chondrosarcoma </i></b></li></ul><p><span class="legendSpanClass"><location value="LU/us.ca.sandgo" idsrc="xmltag.org" >SAN DIEGO</location></span>, <span class="legendSpanClass"><chron>June 15, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:INBX" idsrc="xmltag.org" >Inhibrx Biosciences, Inc.</span> (Nasdaq: INBX) ("<span value="NASDAQ-NMS:INBX" idsrc="xmltag.org" >Inhibrx</span>" or the "Company"), a clinical-stage biopharmaceutical company focused on developing novel biologic therapeutic candidates, today announced that the <span value="ACORN:0682203466" idsrc="xmltag.org" >U.S. Food and Drug Administration</span> (FDA) has accepted for filing its Biologics License Application (BLA) seeking approval of ozekibart (INBRX-109) for http://www.streetinsider.com/PRNewswire/Inhibrx+Announces+U.S.+FDA+Acceptance+of+BLA+for+Ozekibart+in+Patients+with+Conventional+Chondrosarcoma/26645164.html Mon, 15 Jun 2026 09:15:00 -0400 A.06822034 INBX O.20026344 O.21755854 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Inhibrx+Biosciences%2C++++++For%3A+Jun+03++Filed+by%3A+MANHARD+KIMBERLY/26606917.html si-local-file:///var/storage/secattach/20260604/26606917.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Inhibrx+Biosciences%2C++++++For%3A+Jun+03++Filed+by%3A+MANHARD+KIMBERLY/26606917.html Thu, 04 Jun 2026 17:29:00 -0400 INBX O.21755854 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Inhibrx+Biosciences%2C++++++For%3A+Jun+03++Filed+by%3A+MANHARD+KIMBERLY/26606917.html si-local-file:///var/storage/secattach/20260604/26606917.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Inhibrx+Biosciences%2C++++++For%3A+Jun+03++Filed+by%3A+MANHARD+KIMBERLY/26606917.html Thu, 04 Jun 2026 17:29:00 -0400 INBX O.21755854 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Inhibrx+Biosciences%2C++++++For%3A+Jun+03++Filed+by%3A+FORSYTH+DOUGLAS/26606918.html si-local-file:///var/storage/secattach/20260604/26606918.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Inhibrx+Biosciences%2C++++++For%3A+Jun+03++Filed+by%3A+FORSYTH+DOUGLAS/26606918.html Thu, 04 Jun 2026 17:29:00 -0400 INBX O.21755854 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Inhibrx+Biosciences%2C++++++For%3A+Jun+03++Filed+by%3A+FORSYTH+DOUGLAS/26606918.html si-local-file:///var/storage/secattach/20260604/26606918.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Inhibrx+Biosciences%2C++++++For%3A+Jun+03++Filed+by%3A+FORSYTH+DOUGLAS/26606918.html Thu, 04 Jun 2026 17:29:00 -0400 INBX O.21755854 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Inhibrx+Biosciences%2C++++++For%3A+Jun+03++Filed+by%3A+Kayyem+Jon+Faiz/26606919.html si-local-file:///var/storage/secattach/20260604/26606919.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Inhibrx+Biosciences%2C++++++For%3A+Jun+03++Filed+by%3A+Kayyem+Jon+Faiz/26606919.html Thu, 04 Jun 2026 17:29:00 -0400 INBX O.21755854 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Inhibrx+Biosciences%2C++++++For%3A+Jun+03++Filed+by%3A+Kayyem+Jon+Faiz/26606919.html si-local-file:///var/storage/secattach/20260604/26606919.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Inhibrx+Biosciences%2C++++++For%3A+Jun+03++Filed+by%3A+Kayyem+Jon+Faiz/26606919.html Thu, 04 Jun 2026 17:29:00 -0400 INBX O.21755854 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Inhibrx+Biosciences%2C++++++For%3A+Jun+03++Filed+by%3A+Vuori+Kristiina+MD/26606921.html si-local-file:///var/storage/secattach/20260604/26606921.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Inhibrx+Biosciences%2C++++++For%3A+Jun+03++Filed+by%3A+Vuori+Kristiina+MD/26606921.html Thu, 04 Jun 2026 17:29:00 -0400 INBX O.21755854 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Inhibrx+Biosciences%2C++++++For%3A+Jun+03++Filed+by%3A+Vuori+Kristiina+MD/26606921.html si-local-file:///var/storage/secattach/20260604/26606921.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Inhibrx+Biosciences%2C++++++For%3A+Jun+03++Filed+by%3A+Vuori+Kristiina+MD/26606921.html Thu, 04 Jun 2026 17:29:00 -0400 INBX O.21755854 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Inhibrx+Biosciences%2C++++++For%3A+Jun+03/26598680.html si-local-file:///var/storage/secattach/20260603/26598680.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Inhibrx+Biosciences%2C++++++For%3A+Jun+03/26598680.html Wed, 03 Jun 2026 16:02:00 -0400 INBX O.21755854 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Inhibrx+Biosciences%2C++++++For%3A+Jun+03/26598680.html si-local-file:///var/storage/secattach/20260603/26598680.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Inhibrx+Biosciences%2C++++++For%3A+Jun+03/26598680.html Wed, 03 Jun 2026 16:02:00 -0400 INBX O.21755854 http://www.streetinsider.com/Analyst+Comments/Inhibrx+Biosciences+%28INBX%29+Reiterated+at+Buy+by+Stifel+After+Ozekibart+Data+Presentation/26587355.html <p>Stifel analyst Dara Azar reiterated a Buy rating and $325.00 price target on Inhibrx Biosciences (NASDAQ: INBX).</p><p>The analyst commented, "Over the weekend at ASCO26, two Ozekibart posters were presented featuring previously disclosed data in Chondrosarcoma and Colorectal Cancer (CRC) with new granularity mainly on secondary/safety endpoints and presenter commentary. Most incremental for our CRC thesis here was the newly disclosed 11.1m single-agent response durability in Chondrosarcoma, caveated by a small responder sample, that doubles the toplined 5.5m mPFS and is likely a signal of mechanism durability in future earlier-line CRC combinations. This is important because more complex combinations become easier http://www.streetinsider.com/Analyst+Comments/Inhibrx+Biosciences+%28INBX%29+Reiterated+at+Buy+by+Stifel+After+Ozekibart+Data+Presentation/26587355.html Tue, 02 Jun 2026 07:10:13 -0400 INBX http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Inhibrx+Biosciences%2C+++++++++++++++++++Filed+by%3A+VIKING+GLOBAL+INVESTORS+LP/26508118.html si-local-file:///var/storage/secattach/20260515/26508118.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Inhibrx+Biosciences%2C+++++++++++++++++++Filed+by%3A+VIKING+GLOBAL+INVESTORS+LP/26508118.html Fri, 15 May 2026 17:52:00 -0400 INBX O.21755854 http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Inhibrx+Biosciences%2C+++++++++++++++++++Filed+by%3A+VIKING+GLOBAL+INVESTORS+LP/26508118.html si-local-file:///var/storage/secattach/20260515/26508118.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Inhibrx+Biosciences%2C+++++++++++++++++++Filed+by%3A+VIKING+GLOBAL+INVESTORS+LP/26508118.html Fri, 15 May 2026 17:52:00 -0400 INBX O.21755854